Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study

A. Modi, S. Sen, J.D. Adachi, S. Adami, B. Cortet, A.L. Cooper, P. Geusens, D. Mellstrom, J. Weaver*, J.P. van den Bergh, A.M. Nguyen, S. Sajjan

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. INTRODUCTION: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. METHODS: Baseline results are reported here for a prospective study which enrolled postmenopausal, osteoporotic women who were initiating (new users) or continuing (experienced users) osteoporosis treatment at study entry (baseline). A patient survey was administered at baseline and included the occurrence of GI symptoms during 6-month pre-enrolment, treatment adherence (adherence evaluation of osteoporosis (ADEOS), score 0-22), treatment satisfaction (Osteoporosis Treatment Satisfaction Questionnaire for Medications (OPSAT-Q), score 0-100) and HRQoL (EuroQol-5 dimension (EQ-5D) utility, score 0-1; OPAQ-SV, score 0-100). The association between GI symptoms and ADEOS (experienced users), OPSAT-Q (experienced users), and HRQoL (new and experienced users) was assessed by general linear models adjusted for patient characteristics. RESULTS: A total of 2959 patients (2275 experienced and 684 new users) were included. Overall, 68.1 % of patients experienced GI symptoms in the past 6 months. Compared with patients without GI symptoms, patients with GI symptoms had lower mean baseline scores on most measures. The mean adjusted differences were ADEOS, -0.43; OPSAT-Q, -5.68; EQ-5D, -0.04 (new users) and -0.06 (experienced users), all P < 0.01. GI symptoms were also associated with lower OPAQ-SV domain scores: physical function, -4.17 (experienced users); emotional status, -4.28 (new users) and -5.68 (experienced users); back pain, -5.82 (new users) and -11.33 (experienced users), all P < 0.01. CONCLUSIONS: Patients with GI symptoms have lower treatment adherence and treatment satisfaction and worse HRQoL than patients without GI symptoms.
Original languageEnglish
Pages (from-to)1227-1238
Number of pages12
JournalOsteoporosis International
Volume27
Issue number3
Early online date4 Dec 2015
DOIs
Publication statusPublished - Mar 2016

Keywords

  • Bisphosphonates
  • Gastrointestinal
  • Health-related quality of life
  • Osteoporosis
  • Postmenopausal
  • Treatment satisfaction
  • POSTMENOPAUSAL WOMEN
  • BISPHOSPHONATE THERAPY
  • CLINICAL-PRACTICE
  • FRACTURE RISK
  • TRACT SAFETY
  • HEALTH PLAN
  • PERSISTENCE
  • ALENDRONATE
  • RISEDRONATE
  • POPULATION

Cite this